• Is ≥18 years of age at the time of signature of the main study ICF.

• Has an ECOG PS of 0 or 1.

• Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene

• Arms A and B only: Has a tumor with a RAS mutation

• Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC

• Has received prior standard therapy

• Arms A and B only: Must not have received prior RAS-targeted therapy

• Has evidence of measurable disease based on RECIST v1.1.

• Adequate organ function

⁃ Must be able to swallow tablets.

⁃ Negative pregnancy test at screening

⁃ Written informed consent must be obtained according to local guidelines